2025-10-11 - Analysis Report
Okay, here's an analysis of Intuitive Surgical (ISRG) based on the provided data. The report is in English, focusing on key figures and a concise analysis.

**Intuitive Surgical Inc. (ISRG) Report**

**Company Overview:** Intuitive Surgical designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return ISRG:** 61.31%
*   **Cumulative Return VOO:** 99.08%
*   **Spread:** -32.7%
*   **Relative Spread Position:** 1.8% (Indicates ISRG's relative performance is near the lower end of its historical range compared to VOO).

**Analysis:** ISRG has significantly underperformed the S&P 500 over the provided period. The relative spread position suggests this underperformance is near its historical worst, potentially indicating a buying opportunity if you believe ISRG will revert to its mean performance.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | 68.0%   | 77.6%   | 40.0%  | -0.1  | 43.6   |
| 2016-2018  | 64.0%   | 72.2%   | 49.0%  | -0.0  | 57.2   |
| 2017-2019  | 54.0%   | 72.2%   | 31.0%  | 0.2   | 70.6   |
| 2018-2020  | -6.0%   | 80.4%   | -29.0% | 0.3   | 97.7   |
| 2019-2021  | 29.0%   | 80.4%   | -18.0% | 0.6   | 128.8  |
| 2020-2022  | -23.0%  | 80.4%   | -22.0% | 1.2   | 95.1   |
| 2021-2023  | -17.0%  | 77.5%   | -18.0% | 1.7   | 120.9  |
| 2022-2024  | 36.0%   | 77.5%   | 15.0%  | 1.7   | 187.1  |
| 2023-2025  | 24.0%   | 72.7%   | -40.0% | 0.8   | 155.2  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Fluctuates significantly, showing periods of strong growth and declines. Recent periods (2018-2023) show weaker performance.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant volatility and potential for large losses.
*   **Alpha:**  More recent periods have negative alpha, meaning ISRG underperformed relative to its risk-adjusted benchmark.
*   **Beta:** Generally low (close to 0 or slightly positive in early periods, but recently in the 1.x range), suggesting ISRG's price is not strongly correlated with the overall market (S&P 500).  The increasing beta suggests a higher correlation in more recent years.
*   **Cap(B):** Market capitalization in Billions.

**2. Recent Stock Price Movement**

*   **Current Price:** 433.02
*   **Last Market Data:** Price: 433.055, Previous Close: 443.76, Change: -2.41
*   **5-Day Moving Average:** 444.818
*   **20-Day Moving Average:** 442.068
*   **60-Day Moving Average:** 466.8712

**Analysis:** The stock price is below all three moving averages, suggesting a short-term downtrend. The recent price change (-2.41 from the previous close) indicates negative momentum, confirming recent price fluctuations.

**3. Market Risk Indicators & Expected Return**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 46.84 (Neutral - neither overbought nor oversold)
*   **PPO (Percentage Price Oscillator):** 0.23 (Slightly Bullish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20-Day) Relative Spread Change:** 1.8 (+): Short-term increase
*   **Expected Return:** 697.4% (Long-term, relative to S&P 500)

**Analysis:**

*   Despite the recent underperformance, the MRI suggests a high investment recommendation.
*   The RSI is neutral, indicating no strong momentum in either direction.
*   The PPO is slightly bullish, suggesting a possible upward trend.
*   The large positive expected return suggests strong future growth potential relative to the S&P 500, if held long-term.
*   The negative change in price from the previous close indicates a recent dip, which, combined with the MRI and expected return, might present an attractive entry point for long-term investors.

**4. Recent News & Significant Events:**

*   **Acquisition Cleared:** European Commission cleared Intuitive Surgical's acquisition of AB Medica RAS's equipment distribution business.
*   **Analyst Views:** Mentioned in lists of potentially high-flying stocks and magnificent stocks near 52-week lows.
*   **FDA Clearance:** FDA cleared AI integration for the Ion platform.
*   **Earnings Preview:** Q3 earnings report expected.
*   **da Vinci 5 Updates:** Firm released updates for da Vinci 5.

**Analysis:** The news is generally positive. The acquisition clearance expands market reach. FDA clearance for AI integration is a significant technological advancement. Mentions in positive stock lists boost investor sentiment. Upcoming earnings are a potential catalyst for price movement. da Vinci 5 updates show ongoing innovation.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.94)
*   **Target Price:** Avg: 576.95 / High: 685.00 / Low: 350.00
*   **Recent Rating Changes:** (No changes indicated in the data)

**Analysis:** Analysts generally have a positive outlook on ISRG. The average target price suggests significant upside potential from the current price.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2024-07-19 | 1.48 | 2.01 B$   |
| 2025-07-23 | 1.48 | 2.01 B$   |

**Analysis:**  EPS and Revenue generally show an upward trend over the periods provided, indicating growth. The duplication of 2025-07-23's earnings in the provided data needs clarification.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $2.44B    | 66.31%        |
| 2025-03-31 | $2.25B    | 64.69%        |
| 2024-12-31 | $2.41B    | 68.04%        |
| 2024-09-30 | $2.04B    | 67.41%        |
| 2024-06-30 | $2.01B    | 68.30%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-06-30 | $17.85B   | 3.69%  |
| 2025-03-31 | $17.11B   | 4.08%  |
| 2024-12-31 | $16.43B   | 4.17%  |
| 2024-09-30 | $15.58B   | 3.63%  |
| 2024-06-30 | $14.71B   | 3.58%  |

**Analysis:**

*   **Revenue:** Shows a generally increasing trend.
*   **Profit Margin:** Consistently high, indicating strong pricing power and efficient operations.
*   **Equity:** Increasing steadily.
*   **ROE (Return on Equity):**  Fluctuates, but generally healthy, indicating good profitability relative to shareholder equity.

**7. Overall Summary**

Intuitive Surgical (ISRG) is a fundamentally strong company with high profit margins, growing revenue, and positive analyst ratings. However, it has recently underperformed the S&P 500. The stock is currently in a short-term downtrend but the MRI suggests a high investment opportunity and the long-term expected return is very positive. Recent news events are supportive, including acquisition clearance and AI integration for its Ion platform.

**Investment Recommendation:**  Given the company's fundamentals, positive long-term outlook, and recent price weakness, ISRG may present an attractive entry point for long-term investors. However, investors should be aware of the high historical volatility and consider the potential for further short-term price declines. The strong MRI supports a buy recommendation, especially considering the longer-term potential. Diversification is always recommended.
